DexCom and OURA Ink Partnership for Metabolic Health Innovation
DXCM and smart ring maker, OURA, join forces to help individuals make informed decisions regarding diet, exercise and overall well-being.
DexCom Pairs Its Glucose Monitor With Oura's Smart Ring
If you want to monitor your vital signs like an Olympic athlete, you should welcome a pact between glucose-monitor vendor DexCom and Oura smart rings.
Oura CEO on new partnership with Dexcom
Tom Hale, Oura CEO, joins 'Squawk Box' to discuss the company's new partnership with Dexcom, glucose monitors, and much more.
Smart ring maker Ōura valued at over $5 bln after Dexcom funding
Medical device maker Dexcom said on Tuesday it will invest $75 million in Ōura's latest funding round, valuing the smart ring maker at over $5 billion.
3 Top Stocks for Growth Investors to Buy Now
The undervalued stocks of these mid-sized companies with economic moats look attractive.
1 Stock to Buy Near Its 52-Week Low and Hold for 10 Years
This medical device company is down but not out.
Here's Why DexCom (DXCM) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why DexCom Stock Flopped on Friday
Investors likely felt that with a compelling new product on the market, the company should have posted more meaningful growth.
These Analysts Revise Their Forecasts On DexCom Following Q3 Results
DexCom, Inc. DXCM reported better-than-expected third-quarter results on Thursday.
DexCom Q3 Earnings Beat Estimates on Sensor Growth, Stock Rises
DXCM's third-quarter 2024 earnings and revenues surpass expectations, fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.
DexCom Beats Earnings Expectations. Why the Stock Is Trading Lower.
DexCom's U.S. revenue declines 2% in the third quarter from a year earlier.
DexCom Growing Into Its Valuation, But Still No Bargain
DexCom's stock has declined 35% since my last bearish article, validating my "Sell" rating, though past bearish calls were incorrect as the stock previously doubled and tripled. Q3 results showed disappointing 2% revenue growth and a 26% decline in operating income, with U.S. revenue down 1.6% but international revenue up 11.8%. Increased competition from Medtronic and Abbott Laboratories, along with slowing growth rates, raises concerns about Dexcom's ability to maintain its market share.
